Almirall, S.A. (BME:ALM)
Spain · Delayed Price · Currency is EUR | Market Cap | 2.70B +34.7% |
| Revenue (ttm) | 1.11B +12.5% |
| Net Income | 46.15M +354.9% |
| EPS | 0.22 +354.9% |
| Shares Out | 214.79M |
| PE Ratio | 58.33 |
| Forward PE | 31.53 |
| Dividend | 0.19 (1.51%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 27,759 |
| Average Volume | 125,618 |
| Open | 12.52 |
| Previous Close | 12.58 |
| Day's Range | 12.38 - 12.54 |
| 52-Week Range | 9.62 - 13.98 |
| Beta | 0.19 |
| RSI | 50.93 |
| Earnings Date | May 11, 2026 |
About Almirall
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys... [Read more]
Full Company ProfileFinancial Performance
In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.
Financial StatementsNews
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, have announced an expanded collaboration with the Barcelona Supercomputing...
Almirall, S.A.: Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
In the ADlong Phase 3b study*, 94% of patients achieved meaningful skin improvement (EASI-75) with up to four years of lebrikizumab treatment, reinforcing the sustained response achieved over time...
Almirall S.A.: AAD 2026: Almirall Presents New Clinical and Real-world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
Almirall advances scientific leadership in medical dermatology with new data across atopic dermatitis, psoriasis, actinic keratosis and acne, reinforcing its commitment to improving patient outcom...
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
DENVER--(BUSINESS WIRE)--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at t...
Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology
BARCELONA, Spain & PRAGUE--(BUSINESS WIRE)--Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy, a premier scientific me...
Spain's Almirall in talks with 'dozens' of firms to license China assets, CEO says
Almirall is in talks with "dozens" of companies from China to license rights to medicines for other markets, CEO Carlos Gallardo said on Thursday, as the Spanish pharmaceutical company competes with ...
Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships
SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, today holds an institutional event to inaugu...
Almirall profit quadruples in 2025 as dermatology fuels growth push
Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of €46.2 million, which was 357% more than its 2024 profit of €10.1 million. The Barcelona-based pharmaceutical company was...
Almirall Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 12.4% net sales growth and 21% EBITDA increase, driven by European dermatology and biologics. 2026 guidance targets 9%-12% sales growth and continued margin expansion, supported by a robust pipeline and financial flexibility.
Almirall Earnings Call Transcript: Q3 2025
Strong double-digit sales and EBITDA growth in the first nine months of 2025 were driven by Illumetri and Ebgly, with robust European dermatology performance and a solid pipeline. Guidance for 2025 and midterm outlook are reiterated, supported by low leverage and ongoing market expansion.
Almirall Earnings Call Transcript: Q2 2025
Strong H1 2025 results with 13% net sales growth, led by ILUMETRI and Eblis, support reaffirmed guidance and midterm outlook. Robust pipeline progress, disciplined capital allocation, and low leverage position the company for continued growth.
Almirall Transcript: Jefferies Global Healthcare Conference 2025
Dermatology-focused growth is driven by strong launches of Ebglyss and Ilumetri, with double-digit sales growth and margin expansion expected through 2028. A robust pipeline, stable mature portfolio, and minimal US exposure position the company for sustained value creation.
Almirall Earnings Call Transcript: Q1 2025
Q1 2025 saw double-digit sales and EBITDA growth, led by Ilumetri and Eblas, with strong European dermatology performance and robust R&D investment. Guidance for 2025 and midterm outlook were reiterated, with minimal tariff risk and continued focus on innovation and market expansion.
Almirall Earnings Call Transcript: Q4 2024
Delivered double-digit net sales and EBITDA growth in 2024, driven by strong performance in European dermatology, especially from Ilumetri and Ebglyss. 2025 guidance targets further sales acceleration and margin expansion, with continued investment in R&D and new launches.
Almirall Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Strong growth in medical dermatology is driven by leading biologics Ebglyss and Ilumetri, with robust sales, expanding indications, and a promising pipeline. Double-digit sales growth and margin expansion are expected through 2028, supported by disciplined R&D and selective M&A.
Almirall Earnings Call Transcript: Q3 2024
Net sales rose 7.9% to EUR 728 million and EBITDA grew 3% in the first nine months of 2024, driven by strong European dermatology performance and successful launches of Ilumetri and EBGLYSS. Guidance for full-year growth is reiterated, with continued investment in R&D and new markets.
Almirall Earnings Call Transcript: Q2 2024
Strong H1 2024 results with 7% net sales growth and 3.2% EBITDA increase, led by European dermatology. Key products Ilumetri and Ebglyss drove performance, with further launches and R&D progress supporting reiterated full-year guidance.
Almirall Earnings Call Transcript: Q1 2024
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered str...